Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 9/20 | 0.63 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.63 |
| ▸ | PDE4A | P27815 | 3/20 | 0.58 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.58 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL150602 | 0.87 | ADORA2B (0.59) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL7958463 | 0.84 | ADORA2B (0.51) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL897035 | 0.83 | ADORA2B (0.55) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL2917584 | 0.83 | ADORA2B (0.55) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL10535015 | 0.82 | ADORA2A (0.57) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL7035609 | 0.81 | ADORA2B (0.52) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL7801074 | 0.78 | ADORA2B (0.56) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| 1-Methylxanthine SCHEMBL10996 | 0.77 | ADORA2B (1.00) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL7972790 | 0.77 | ADORA2B (0.55) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL2842234 | 0.77 | ADORA2B (0.55) | ADORA2BADORA2APDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765757-B2 | 3-heterocyclic substituted indole derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20110165118-A1 | 3-HETEROCYCLIC SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2011-07-07 | — | — | US | disclosed |
| US-20110165118-A1 | 3-HETEROCYCLIC SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165118-A1 | 3-HETEROCYCLIC SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, HTR3C | ADORA2B 2248/4885ADORA2A 1255/4885PDE4A 2643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.